SCHEMBL5412995

SCHEMBL5412995

Cc1ccccc1N(C)CCN(C(=O)C(c1ccc(Cl)cc1)N1CCN(c2ncnc3[nH]nc(Br)c23)CC1=O)c1ccccc1

nearest known ligand 0.37

Predicted protein targets (top 7)

geneUniProtsupporting neighboursconfidence
AKT1 P31749 18/20 0.37
AKT2 P31751 3/20 0.37
AKT3 Q9Y243 3/20 0.37
ROCK2 O75116 3/20 0.32
KCNH2 Q12809 1/20 0.32
LIMK2 P53671 1/20 0.31
RPS6KB1 P23443 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL473313 0.79 AKT1 (0.41) AKT1AKT2AKT3ROCK2RPS6KB1
SCHEMBL23532317 0.71 AKT1 (0.54) AKT1AKT2AKT3ROCK2KCNH2
SCHEMBL473310 0.69 RPS6KB1 (0.52) AKT1AKT2AKT3ROCK2RPS6KB1
SCHEMBL473308 0.67 AKT1 (0.46) AKT1AKT2RPS6KB1
SCHEMBL10159516 0.66 AKT1 (0.38) AKT1AKT2AKT3
SCHEMBL2299211 0.66 RPS6KB1 (0.56) AKT1AKT2RPS6KB1
SCHEMBL23532315 0.65 AKT1S1 (0.59) AKT1AKT2AKT3RPS6KB1
SCHEMBL473355 0.64 AKT1 (0.43) AKT1AKT2AKT3ROCK2KCNH2
SCHEMBL473298 0.63 AKT1 (0.43) AKT1AKT2AKT3ROCK2KCNH2
SCHEMBL473351 0.62 RPS6KB1 (0.54) AKT1AKT2AKT3ROCK2KCNH2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1848719-A1 [1H-PYRAZOLO[3,4-D]PYRIMIDIN-4-YL]-PIPERIDINE OR -PIPERAZINE COMPOUNDS AS SERINE-THREONINE KINASE MODULATORS (P70S6K, ATK1 AND ATK2) FOR THE TREATMENT OF IMMUNOLOGICAL, INFLAMMATORY AND PROLIFERATIVE DISEASES Exelixis, Inc. (US) 2007-10-31 EP disclosed
WO-2006071819-A1 [1H-PYRAZOLO[3, 4-D]PYRIMIDIN-4-YL]-PIPERIDINE OR -PIPERAZINE COMPOUNDS AS SERINE-THEORONINE KINASE MODULATORS (P70S6K, ATK1 AND ATK2) FOR THE TREATMENT OF IMMUNOLOGICAL, INFLAMMATORY AND PROLIFERATIVE DISEASES EXELIXIS, INC. (US) 2006-07-06 WO disclosed